drugset / Trial / NCT00036062

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

NCT00036062

Phase 1/2 Completed 600 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.

Timeline

Start
2001-08
Primary completion
Completion
2002-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sivelestat Small molecule